PAZOPANIB for Thyroid cancer: Side Effects & Safety Data
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
There are 264 adverse event reports in the FDA FAERS database where PAZOPANIB was used for Thyroid cancer.
Most Reported Side Effects for PAZOPANIB
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| Death | 3,767 | 17.8% | 3,764 | 211 |
| Diarrhoea | 2,907 | 13.7% | 213 | 501 |
| Fatigue | 1,883 | 8.9% | 173 | 315 |
| Nausea | 1,879 | 8.9% | 192 | 413 |
| Malignant neoplasm progression | 1,471 | 6.9% | 570 | 372 |
| Drug ineffective | 1,135 | 5.4% | 160 | 141 |
| Decreased appetite | 1,116 | 5.3% | 196 | 321 |
| Vomiting | 1,072 | 5.1% | 153 | 366 |
| Hypertension | 1,004 | 4.7% | 104 | 271 |
| Malaise | 764 | 3.6% | 148 | 254 |
| Disease progression | 739 | 3.5% | 185 | 82 |
| Asthenia | 727 | 3.4% | 161 | 280 |
| Product use in unapproved indication | 724 | 3.4% | 153 | 60 |
| Weight decreased | 697 | 3.3% | 85 | 168 |
| Hair colour changes | 679 | 3.2% | 41 | 83 |
Other Indications for PAZOPANIB
Product used for unknown indication (5,026)
Renal cancer (3,759)
Renal cell carcinoma (2,799)
Soft tissue sarcoma (1,400)
Metastatic renal cell carcinoma (1,353)
Neoplasm malignant (716)
Malignant connective tissue neoplasm (417)
Renal cancer metastatic (366)
Sarcoma (296)
Clear cell renal cell carcinoma (202)
Other Drugs Used for Thyroid cancer
LENVATINIB (2,668)
CABOZANTINIB S-MALATE (1,615)
VANDETANIB (591)
DABRAFENIB (583)
TRAMETINIB DIMETHYL SULFOXIDE (482)
SORAFENIB (399)
LEVOTHYROXINE (299)
PRALSETINIB (199)
CABOZANTINIB (125)
VEMURAFENIB (119)